QLT sells superseded AMD therapy Visudyne to Valeant
This article was originally published in Clinica
Executive Summary
Valeant has acquired Visudyne (verteporfin for injection), a drug-and-laser therapy which once represented a breakthrough therapy for wet age-related macular degeneration (AMD), from Canadian firm QLT. Valeant is paying $112.5 million up front and up to $20 million in milestones for all US rights and non-US royalties.